3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
42
Ovarian Neoplasms
33
Fallopian Tube Neoplasms
15
Neoplasms
12
Carcinoma, Ovarian Epithelial
10
Uterine Cervical Neoplasms
7
Recurrence
6
Neuroblastoma
5
Lung Neoplasms
5
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Sarcoma, Ewing
3
Endometrial Neoplasms
3
Uterine Cervical Dysplasia
2
Sarcoma, Clear Cell
2
Sarcoma
2
Rhabdomyosarcoma
2
Myoepithelioma
2
Medulloblastoma
2
Liposarcoma, Myxoid
2
Histiocytoma, Angiomatoid Fibrous
2
Hereditary Sensory and Autonomic Neuropathies
2
Diffuse Intrinsic Pontine Glioma
2
Desmoplastic Small Round Cell Tumor
2
Chondrosarcoma, Extraskeletal Myxoid
2
Carcinoma
2
Solid Tumours
1
Solid Tumors
1
Solid Tumor
1
SCLC
1
Interventions
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
Topotecan
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled